TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
+10.56%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.98B
AUM Growth
+$171M
(+9.4%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
5.98%
Top 10 Holdings %
Top 10 Hldgs %
35.03%
Holding
220
New
18
Increased
34
Reduced
52
Closed
20
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$28.3M |
| 2 |
Merus
MRUS
|
$26.3M |
| 3 |
Mettler-Toledo International
MTD
|
$22.9M |
| 4 |
Boeing
BA
|
$20.9M |
| 5 |
Spyre Therapeutics
SYRE
|
$17.2M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$37.7M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$29M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$10.1M |
| 5 |
CRISPR Therapeutics
CRSP
|
$9.07M |
Sector Composition
| 1 | Healthcare | 94.16% |
| 2 | Technology | 1.37% |
| 3 | Industrials | 1.32% |
| 4 | Communication Services | 1.26% |
| 5 | Consumer Discretionary | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
ANI Pharmaceuticals
ANIP
$2.08B
| $20.7M | 1.05% |
317,500
| – | – |
|
27
NVIDIA
NVDA
$4.16T
| $20.6M | 1.04% |
130,509
-12,060
| -8% | -$1.91M |
|
28
Jazz Pharmaceuticals
JAZZ
$7.84B
| $20.2M | 1.02% |
190,000
| – | – |
|
29
Insmed
INSM
$30B
| $20.1M | 1.02% |
200,000
+100,000
| +100% | +$10.1M |
|
|
30
Dynavax Technologies
DVAX
$1.19B
| $19.3M | 0.98% |
1,949,500
-3,800,500
| -66% | -$37.7M |
|
31
Meta Platforms (Facebook)
META
$1.89T
| $19.2M | 0.97% |
26,008
-1,567
| -6% | -$1.16M |
|
32
ADMA Biologics
ADMA
$4B
| $19.1M | 0.97% |
1,050,000
| – | – |
|
33
Keros Therapeutics
KROS
$627M
| $18.9M | 0.96% |
1,418,984
+318,984
| +29% | +$4.26M |
|
34
Neurocrine Biosciences
NBIX
$13.6B
| $18.9M | 0.95% |
150,000
| – | – |
|
|
AVDL
35
Avadel Pharmaceuticals
AVDL
$1.42B
| $18.6M | 0.94% |
2,097,500
| – | – |
|
36
Atea Pharmaceuticals
AVIR
$267M
| $17.6M | 0.89% |
4,889,200
+89,200
| +2% | +$321K |
|
37
GSK
GSK
$79.7B
| $15.4M | 0.78% |
400,000
| – | – |
|
|
CYBN
38
Cybin
CYBN
$144M
| $15.4M | 0.78% |
1,830,097
| – | – |
|
39
Liquidia Corp
LQDA
$2.46B
| $14.3M | 0.72% |
1,143,759
-56,241
| -5% | -$701K |
|
40
Zymeworks
ZYME
$1.08B
| $13.8M | 0.7% |
1,100,000
| – | – |
|
41
UroGen Pharma
URGN
$883M
| $13.7M | 0.69% |
+1,000,000
| New | +$13.7M |
|
42
Journey Medical
DERM
$184M
| $13.3M | 0.67% |
1,854,596
| – | – |
|
|
CRGX
43
DELISTED
CARGO Therapeutics
CRGX
| $12.6M | 0.64% |
3,059,630
| – | – |
|
44
Teladoc Health
TDOC
$1.35B
| $12.2M | 0.62% |
1,400,000
| – | – |
|
45
Nkarta
NKTX
$148M
| $11.7M | 0.59% |
7,055,576
| – | – |
|
46
Elanco Animal Health
ELAN
$8.61B
| $11.4M | 0.58% |
800,100
| – | – |
|
47
Vanda Pharmaceuticals
VNDA
$272M
| $11.1M | 0.56% |
2,353,307
| – | – |
|
48
Altimmune
ALT
$316M
| $10.6M | 0.54% |
2,750,000
| – | – |
|
49
AstraZeneca
AZN
$254B
| $10.5M | 0.53% |
150,000
-100,000
| -40% | -$6.99M |
|
50
Travere Therapeutics
TVTX
$1.77B
| $10.4M | 0.52% |
+700,000
| New | +$10.4M |
|